Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xin-Guan-1 is a Traditional Chinese Medicine (TCM) herbal formula developed by the Guangdong Provincial Hospital of Chinese Medicine for the treatment of COVID-19. It was investigated in observational clinical trials to evaluate its efficacy and safety when combined with standard of care in patients across the severity spectrum, including mild, moderate, and severe novel coronavirus pneumonia. As a botanical combination, its mechanism of action is likely pleiotropic, involving immunomodulation and anti-inflammatory pathways to mitigate the symptoms of viral pneumonia. The formula was part of a broader effort in China to integrate TCM into the emergency response to the SARS-CoV-2 pandemic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xin-Guan-1 formula.